Attività dipartimentali | Studi Osservazionali

In the EU, treating patients with prostate (PCa) and kidney cancer (KC) costs more than €6.6 billion annually. Yet, PCa and KC are often managed inadequately, which is associated with high costs and negative consequences such as hospitalisation, psychosocial stress and poorer chances of survival. Diagnostic and therapeutic effectiveness depends on multimodal information, including cancer type, stage, and location as well as the patient’s age and health. Current clinical methods do not effectively use the large amount of mostly unstructured data.